ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2025
Early influenza virus characterisation and vaccine effectiveness in England in autumn 2025, a period dominated by influenza A(H3N2) subclade K.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Reduced T cell epitope cross-conservation and immunogenic potential is associated with emergence of a dominant influenza subclade K in 2025.Human vaccines & immunotherapeutics · 2026Article
- Effectiveness of the 2025-2026 seasonal influenza vaccine among U.S. veterans: an observational study.EClinicalMedicine · 2026Article
- Near real-time data on the human neutralizing antibody landscape to influenza virus in summer of 2026 shows antigenic advance of H3N2 subclade K region D mutants and H1N1 D.3.1.1 Sa mutants.bioRxiv : the preprint server for biology · 2026Article
- Discovery and Structure-Activity Relationship Studies of Thienopyrroles as Group 2 Influenza A Entry Inhibitors.ACS medicinal chemistry letters · 2026Article
- Host cell entry and neutralisation sensitivity of H3N2 influenza A virus subclade K.NPJ vaccines · 2026Article
- Article
- Article
- Early circulation of influenza A(H3N2) subclade K: antigenic drift and vaccine effectiveness.Osong public health and research perspectives · 2026Article
- Loss of hemagglutination ability by H3N2 influenza A virus, subclade K.bioRxiv : the preprint server for biology · 2026Article
- Assessment of human immunity to A/H3N2 influenza subclade K during 2025 emergence.EBioMedicine · 2026Article
- Seasonal vaccine-induced immunity shows preserved cross-reactivity to H3N2 subclade K in adults.EBioMedicine · 2026Article
- Northern Hemisphere 2025/26 influenza vaccine effectiveness during months with influenza A(H3N2) subclade K predominance- Suzhou, Eastern China.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026Article
- Influenza Activity and Estimated Vaccine Effectiveness During the 2025-2026 Influenza Season.JAMA network open · 2026Article
- Article
- Influenza A(H3N2) Subclade K: Epidemiology, Molecular Evolution and Vaccine Effectiveness in Europe.Pathogens (Basel, Switzerland) · 2026Review
- Influenza A(H3N2) Subclade K (J.2.4.1): Molecular Characterization, Antigenic Divergence, and Global Spread During the 2025/26 Season.Infectious disease reports · 2026Article
- Article
- Tackling NHS winter pressures due to respiratory disease: the UK Centre for Applied Respiratory Research Innovation and Impact (CARRii).NPJ primary care respiratory medicine · 2026Review
- Human Influenza Virus Infection: A Focus on Key Host Determinants Linked to Clinical Disease Severity.Viruses · 2026Review
- Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - California, October 2025-January 2026.MMWR. Morbidity and mortality weekly report · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza A(H3N2) subclade K (J.2.4.1) has dominated the 2025/26 season start in England. Post-infection ferret antisera raised against northern hemisphere 2025/26 vaccine strains showed reduced reactivity to subclade K viruses in England, aligning with World Health Organization reports. Nevertheless, early post-vaccination, vaccine effectiveness against influenza-related emergency department attendances and hospital admissions remained within typical ranges, at 72-75% in children and adolescents (< 18 years) and 32-39% in adults. Hence, vaccination remains effective against clinical disease caused by influenza A(H3N2) viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.